We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


OMT Announces New Antibody Discovery Program

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "OMT Announces New Antibody Discovery Program"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Open Monoclonal Technology, Inc. (OMT) has announced an antibody discovery collaboration with Merck KGaA.

OMT and Merck KGaA have entered into a collaboration whereby OMT will use its OmniRats™ to generate antibodies against several targets selected by Merck KGaA.

Merck KGaA has the rights to further develop and commercialize the antibodies derived from the OmniRat™ as therapeutic and diagnostic products.

Under the terms of the agreement, OMT will receive upfront payment, success-based milestones, and royalties.

"We are pleased to be collaborating with Merck KGaA. OMT's OmniRat™ generates antibodies with great specificity, affinity and manufacturability. Our partners are looking for technologies that can eliminate time-consuming humanization of antibodies or optimization of leads identified using display technology. The OmniRat™ can save significant development time and is available for all targets", said Roland Buelow, Founder and CEO of OMT.